Home | Back to newsletter main page
| |||||||
 |
|||||||
March 12, 2012 |
|||||||
MESSAGE FROM THE DIRECTORNew FacultyPlease join me in welcoming three new faculty members who were recently recruited to the Cancer Center:
A reception will be held today, Monday, March 12 at 5 pm in Wolstein Research Building 1-203, which is the carpeted area on the first floor. I hope you will attend and greet your new colleagues. Stan Gerson, MD CASE CCC IN THE NEWSMedical Researchers Up in Arms About Delayed Cures and Shuttered Labs as Obama Proposes Flat Research Grant Budget Cuyahoga County Provides Extensive Review of State of Cancer in the County The Elusive Nature Of Cancer MARK YOUR CALENDARSCancer Center Seminar Series: The Chemoprevention of Colorectal Cancer: the long saga of difluoromethyornithine (1980-?2016)
Friday, March 16 Please join us March 16 for the next Cancer Center Seminar Series where Dr. Frank Meyskens, Jr., Director of the Chao Family Comprehensive Cancer Center at the University of California Irvine, will present The Chemoprevention of Colorectal Cancer: the long saga of difluoromethyornithine (1980-?2016). Over the past 30 years, Dr. Meyskens has been involved with and PI of multiple treatment and prevention phase II and III trials. He has been Associate Director of Cancer Control and Prevention for SWOG since 2007. His prevention and control research has been funded by the NIH/NCI, and led to a very successful randomized placebo-controlled trial of the combination of difluoromethylornithine + sulindac in which advanced adenomas were reduced over 90% in at risk population. Subsequently, Dr. Meyskens co-founded Cancer Prevention Pharmaceuticals to move these findings to a registration trial and clinical benefit. His lab remains active and fully equipped for modern molecular research, and in the last five years has taken on the difficult task of developing a mechanistic basis for the chemoprevention of cutaneous melanoma. FUNDING OPPORTUNITIESSpecialized Program of Research Excellence in Gastrointestinal Malignancies (GI SPORE)All Faculty members are invited to submit outlines for pilot projects to be funded by the NIH P50 GI SPORE. Proposals must be submitted through CTSC Webgrants. Please note that a SPORE project must be directed toward translational research of a GI malignancy. At least one specific aim should involve either direct patient contact or the study of patient derived tissue samples. More information on grant application is available at http://webgrants.case.edu or through John Pounardjian, hxp125@case.edu, 368-1976. Information is also posted on the CWRU GI SPORE website. Deadline: April 2 AACR Calls for Letters of Intent for a New Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Research Dream TeamStand Up To Cancer (SU2C) and the Cancer Research Institute (CRI), along with the American Association for Cancer Research (AACR), call upon the cancer research community to submit Letters of Intent for a new Dream Team — the SU2C-CRI Cancer Immunology Translational Research Dream Team. Significant scientific developments in the field of cancer immunology and the recent FDA approvals of two cancer immunotherapies highlight the field's potential to transform cancer treatment. The SU2C-CRI Cancer Immunology Translational Research Dream Team Grant will provide funding of $6 million over a three-year period for translational cancer research projects that address laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer. Projects should also deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. LOI Deadline: April 9 ANNOUNCEMENTSCancer.gov Goes MobileThe NCI announces the launch of its mobile website, m.cancer.gov. Designed specifically for mobile users on any mobile platform, the site offers much of the same high-quality information found on cancer.gov's desktop site. Available in English and Spanish, m.cancer.gov provides cancer patients, their loved ones, and their caregivers with easy access to the cancer information they need, when they need it. NCI CANCER BULLETINMarch 6, 2012News Commentary In Depth Updates | EVENTS
**All events are open to anyone interested in attending March 12SDIG Seminar New Case CCC Faculty Welcome Reception March 13Immunology Invited Speaker Seminar Series Department of Cancer Biology Invited Speaker Seminar NCI Office of Cancer Centers Learning Series Webinar Cancer Cell Signaling Program Meeting of the Cytokine Signaling, Inflammation, and Cancer Focus Group March 14Hematology and Oncology Division Research Conference Skeletal Research Center Seminar Cell Death Regulation Program Meeting March 15CWRU Office of Research Compliance Webinar National Center for Regenerative Medicine Seminar March 16Hematology/Oncology Fellows Taussig Cancer Institute Grand Rounds Cancer Center Seminar Series Molecular Biology and Microbiology Thesis Defense Cancer Center Research in Progress Seminar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTSCase CCC Clinical Research Retreat Breast Cancer 2012: Risk Assessment through Survivorship Ca-PRI Annual Meeting: Learning from Our Differences ADDITIONAL UPCOMING SEMINARS & EVENTSNCI Second Symposium on Translational Genomics Midwest Blood Club Symposium Sternlicht Memorial Lectureship in Cancer Biology and Pharmacology Grant Writing and Reviewing Workshop Department of Biomedical Engineering Special Seminar |
||||||
|
|
|||||||
PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES |
|||||||
|
Childhood Brain Tumor Foundation (CBTF) |
DOD Ovarian Cancer Research Program Ovarian Cancer Academy Award |
||||||
|
|
|||||||
NIH BULLETIN – Notices and Funding OpportunitiesDiet, Epigenetic Events, and Cancer Prevention (R01)(PA-09-234) Diet, Epigenetic Events, and Cancer Prevention (R21)(PA-09-235) Paul Calabresi Career Development Award for Clinical Oncology (K12)(PAR-10-155) Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21)(PA-09-238) Image-guided Drug Delivery in Cancer (R01)(PA-09-253) National Cancer Institute (NCI) Cancer Education and Career Development Program (R25)(PAR-10-165) |
|||||||
| Produced by: Gillian Irwin Todd 11100 Euclid Avenue, Wearn 149 Cleveland, Ohio 44106-5065 216-844-8317 phone 216-844-7832 fax gillian.irwin@case.edu |
HELP US HELP YOU!If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to gillian.irwin@case.edu. |
||||||
|
|||||||
